FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for Levetiracetam from Prasco Laboratories, resulting in updated labeling for this antiepileptic drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Generalized Tonic-clonic Seizures
• Idiopathic Generalized Epilepsy
• Juvenile Myoclonic Epilepsy
• Myoclonic Seizures
• Partial-onset Seizures

Drugs mentioned

• LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)